Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price dropped 5.8% on Thursday . The stock traded as low as $1.09 and last traded at $1.13. Approximately 10,447 shares were traded during trading, a decline of 31% from the average daily volume of 15,111 shares. The stock had previously closed at $1.20.
Humacyte Trading Down 5.8 %
The business’s fifty day moving average price is $1.58 and its 200-day moving average price is $1.77.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- CD Calculator: Certificate of Deposit Calculator
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to invest in marijuana stocks in 7 steps
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Why Are Stock Sectors Important to Successful Investing?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
